Endra Life Sciences Soars 29.17% on Zacks Rank Upgrade
On April 30, 2025, Endra Life Sciences surged 29.17% in pre-market trading, marking a significant rise in its stock value.
Endra Life Sciences has been upgraded to a Zacks Rank #1 (Strong Buy), indicating a growing optimism about the company's earnings prospects. This upgrade reflects the market's positive outlook on the company's future performance.
Analysts have set a 12-month price target for Endra Life Sciences, predicting a substantial increase from the current stock price. This target suggests that the company is expected to experience significant growth in the coming year.
